CA2468390A1 - Treatment of wounds and compositions employed - Google Patents
Treatment of wounds and compositions employed Download PDFInfo
- Publication number
- CA2468390A1 CA2468390A1 CA002468390A CA2468390A CA2468390A1 CA 2468390 A1 CA2468390 A1 CA 2468390A1 CA 002468390 A CA002468390 A CA 002468390A CA 2468390 A CA2468390 A CA 2468390A CA 2468390 A1 CA2468390 A1 CA 2468390A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- wound
- ions
- pharmaceutically effective
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010052428 Wound Diseases 0.000 title claims abstract description 152
- 208000027418 Wounds and injury Diseases 0.000 title claims abstract description 143
- 239000000203 mixture Substances 0.000 title claims abstract description 89
- 238000011282 treatment Methods 0.000 title claims abstract description 62
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims abstract description 27
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 10
- 239000003937 drug carrier Substances 0.000 claims abstract description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 24
- 230000035876 healing Effects 0.000 claims description 24
- 230000001684 chronic effect Effects 0.000 claims description 14
- 150000002500 ions Chemical class 0.000 claims description 13
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 7
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 7
- 229910052791 calcium Inorganic materials 0.000 claims description 7
- 239000011575 calcium Substances 0.000 claims description 7
- 229910052701 rubidium Inorganic materials 0.000 claims description 7
- IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 claims description 7
- 229910052725 zinc Inorganic materials 0.000 claims description 7
- 239000011701 zinc Substances 0.000 claims description 7
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 6
- 229910052700 potassium Inorganic materials 0.000 claims description 6
- 239000011591 potassium Substances 0.000 claims description 6
- 230000005465 channeling Effects 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 230000007935 neutral effect Effects 0.000 claims 2
- 239000002516 radical scavenger Substances 0.000 claims 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 abstract description 7
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 abstract description 7
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 abstract description 5
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 abstract description 5
- 229910001424 calcium ion Inorganic materials 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 4
- 229910001414 potassium ion Inorganic materials 0.000 abstract description 4
- 229910001419 rubidium ion Inorganic materials 0.000 abstract description 4
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 21
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 21
- 238000001574 biopsy Methods 0.000 description 16
- 238000001000 micrograph Methods 0.000 description 13
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
- 108010035532 Collagen Proteins 0.000 description 11
- 102000008186 Collagen Human genes 0.000 description 11
- 229920001436 collagen Polymers 0.000 description 11
- 210000002744 extracellular matrix Anatomy 0.000 description 10
- FGDZQCVHDSGLHJ-UHFFFAOYSA-M rubidium chloride Chemical compound [Cl-].[Rb+] FGDZQCVHDSGLHJ-UHFFFAOYSA-M 0.000 description 10
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 10
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 9
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 9
- 210000002950 fibroblast Anatomy 0.000 description 9
- 102000005741 Metalloproteases Human genes 0.000 description 8
- 108010006035 Metalloproteases Proteins 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 7
- 238000003556 assay Methods 0.000 description 6
- 230000029663 wound healing Effects 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 239000001508 potassium citrate Substances 0.000 description 5
- 229960002635 potassium citrate Drugs 0.000 description 5
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 5
- 235000011082 potassium citrates Nutrition 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 229940102127 rubidium chloride Drugs 0.000 description 5
- 150000003431 steroids Chemical class 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000011592 zinc chloride Substances 0.000 description 5
- 235000005074 zinc chloride Nutrition 0.000 description 5
- 102000009123 Fibrin Human genes 0.000 description 4
- 108010073385 Fibrin Proteins 0.000 description 4
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 4
- 230000002500 effect on skin Effects 0.000 description 4
- 229950003499 fibrin Drugs 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- 208000004210 Pressure Ulcer Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000007634 remodeling Methods 0.000 description 3
- IHCDKJZZFOUARO-UHFFFAOYSA-M sulfacetamide sodium Chemical compound O.[Na+].CC(=O)[N-]S(=O)(=O)C1=CC=C(N)C=C1 IHCDKJZZFOUARO-UHFFFAOYSA-M 0.000 description 3
- ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 206010056340 Diabetic ulcer Diseases 0.000 description 2
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000005230 Leg Ulcer Diseases 0.000 description 2
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010040943 Skin Ulcer Diseases 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 206010044546 Traumatic ulcer Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910001410 inorganic ion Inorganic materials 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000013310 pig model Methods 0.000 description 2
- 229960003975 potassium Drugs 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- -1 superoxide anions Chemical class 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- GKFPPCXIBHQRQT-UHFFFAOYSA-N 6-(2-carboxy-4,5-dihydroxy-6-methoxyoxan-3-yl)oxy-4,5-dihydroxy-3-methoxyoxane-2-carboxylic acid Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(OC)C(C(O)=O)O1 GKFPPCXIBHQRQT-UHFFFAOYSA-N 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 229940123973 Oxygen scavenger Drugs 0.000 description 1
- AMFGWXWBFGVCKG-UHFFFAOYSA-N Panavia opaque Chemical compound C1=CC(OCC(O)COC(=O)C(=C)C)=CC=C1C(C)(C)C1=CC=C(OCC(O)COC(=O)C(C)=C)C=C1 AMFGWXWBFGVCKG-UHFFFAOYSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 108010064622 Procollagen N-Endopeptidase Proteins 0.000 description 1
- 102000015339 Procollagen N-endopeptidase Human genes 0.000 description 1
- 108010003894 Protein-Lysine 6-Oxidase Proteins 0.000 description 1
- 102100026858 Protein-lysine 6-oxidase Human genes 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010054880 Vascular insufficiency Diseases 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003377 anti-microbal effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- CUBCNYWQJHBXIY-UHFFFAOYSA-N benzoic acid;2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1O CUBCNYWQJHBXIY-UHFFFAOYSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- UFRKOOWSQGXVKV-UHFFFAOYSA-N ethene;ethenol Chemical compound C=C.OC=C UFRKOOWSQGXVKV-UHFFFAOYSA-N 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 239000004715 ethylene vinyl alcohol Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 230000037313 granulation tissue formation Effects 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000013003 healing agent Substances 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108010067415 progelatinase Proteins 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000019254 respiratory burst Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 208000023577 vascular insufficiency disease Diseases 0.000 description 1
- 201000002282 venous insufficiency Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/18—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Materials Engineering (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33433701P | 2001-11-29 | 2001-11-29 | |
| US60/334,337 | 2001-11-29 | ||
| PCT/US2002/038175 WO2003045366A1 (en) | 2001-11-29 | 2002-11-27 | Treatment of wounds and compositions employed |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2468390A1 true CA2468390A1 (en) | 2003-06-05 |
Family
ID=23306754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002468390A Abandoned CA2468390A1 (en) | 2001-11-29 | 2002-11-27 | Treatment of wounds and compositions employed |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US20030133991A1 (enExample) |
| EP (1) | EP1461024A4 (enExample) |
| JP (1) | JP2005515191A (enExample) |
| AU (1) | AU2002359529B2 (enExample) |
| CA (1) | CA2468390A1 (enExample) |
| MX (1) | MXPA04005219A (enExample) |
| NZ (1) | NZ533252A (enExample) |
| WO (1) | WO2003045366A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040023937A1 (en) * | 2002-05-24 | 2004-02-05 | Greystone Medical Group, Inc. | Anti-cancer formulation |
| JP2006511585A (ja) * | 2002-12-23 | 2006-04-06 | グレイストーン メディカル グループ、インコーポレイテッド | 慢性創傷管理における活性酸素種の減少 |
| US20050175715A1 (en) * | 2003-08-25 | 2005-08-11 | Monroe Stephen H. | Cellular depolarization and regulation of matrix metalloproteinases |
| WO2006002326A2 (en) * | 2004-06-22 | 2006-01-05 | Greystone Medical Group, Inc. | Methods for treatment of wounds using time release compositions |
| US20070212342A1 (en) * | 2005-12-20 | 2007-09-13 | Swiss-American Products, Inc. | Protease compositions for the treatment of damaged tissue |
| US8795730B2 (en) * | 2006-01-31 | 2014-08-05 | David John Vachon | Compositions and methods for promoting the healing of tissue of multicellular organisms |
| US7687650B2 (en) | 2006-02-03 | 2010-03-30 | Jr Chem, Llc | Chemical compositions and methods of making them |
| PL1993569T3 (pl) | 2006-02-03 | 2014-11-28 | Obagi Cosmeceuticals Llc | Terapia przeciw starzeniu z użyciem kompozycji miedzi i cynku |
| US7897800B2 (en) | 2006-02-03 | 2011-03-01 | Jr Chem, Llc | Chemical compositions and methods of making them |
| WO2007143586A2 (en) * | 2006-06-01 | 2007-12-13 | Pharmaionx, Inc. | Composition for wound care and method of using same |
| US7867522B2 (en) | 2006-09-28 | 2011-01-11 | Jr Chem, Llc | Method of wound/burn healing using copper-zinc compositions |
| EP2152359A2 (en) | 2007-05-25 | 2010-02-17 | Compex Medical S.A. | Wound healing electrode set |
| ITBS20070178A1 (it) * | 2007-11-15 | 2009-05-16 | Paoli Ambrosi Gianfranco De | Composizione per uso farmaceutico e/o cosmetico e/o in forma di dispositivo medico per favorire processi di cicatrizzazione, per il trattamento di cicatrici ipertrofiche e per migliorare le proprieta' biomeccaniche della cute |
| US20100260863A1 (en) * | 2007-12-11 | 2010-10-14 | Monroe Stephen H | Composition of aqueous buffer solution for the treatment of cellular environment and ion channels and methods for using same |
| US8273791B2 (en) | 2008-01-04 | 2012-09-25 | Jr Chem, Llc | Compositions, kits and regimens for the treatment of skin, especially décolletage |
| CA2750636C (en) | 2009-01-23 | 2017-07-25 | Jr Chem, Llc | Rosacea treatments and kits for performing them |
| US20110008271A1 (en) * | 2009-07-13 | 2011-01-13 | Jr Chem, Llc | Rosacea treatments using polymetal complexes |
| US8952057B2 (en) | 2011-01-11 | 2015-02-10 | Jr Chem, Llc | Compositions for anorectal use and methods for treating anorectal disorders |
| GB201116523D0 (en) * | 2011-09-23 | 2011-11-09 | Systagenix Wound Man Ip Co Bv | Wound prognosis |
| EP2896963B1 (en) | 2011-01-31 | 2019-01-30 | Woundchek Laboratories B.V. | Wound prognosis |
| US9351995B1 (en) | 2011-04-29 | 2016-05-31 | Red Oax Holdings, LLC | Compositions and methods of enhancing wound healing |
| EP2734243A1 (en) * | 2011-07-20 | 2014-05-28 | 3M Innovative Properties Company | Dressing with ion-carrying composition |
| JP6133858B2 (ja) * | 2011-07-28 | 2017-05-24 | スリーエム イノベイティブ プロパティズ カンパニー | 創傷治癒組成物及び使用方法 |
| AU2013367193A1 (en) * | 2012-12-26 | 2015-07-16 | A-Z Ltd. | Wound healing accelerator |
| US10780114B2 (en) | 2015-06-12 | 2020-09-22 | Jfe Mineral Company, Ltd. | Therapeutic agent for skin wound or rough skin |
| DK3308794T3 (da) * | 2015-06-12 | 2022-11-07 | Jfe Mineral Co Ltd | Terapeutisk middel til sår eller ru hud |
| US10987380B2 (en) | 2016-12-09 | 2021-04-27 | Jfe Mineral Company, Ltd. | Hydrozincite containing zinc carbonate hydroxide hydrate and method of making |
| RU2636523C1 (ru) * | 2017-02-09 | 2017-11-23 | федеральное государственное бюджетное образовательное учреждение высшего образования "Воронежский государственный медицинский университет имени Н.Н. Бурденко" Министерства здравоохранения Российской Федерации (ФГБОУ ВО ВГМУ им. Н.Н. Бурденко Минздрава России) | Лекарственное средство для ускорения заживления ран, содержащее хлорид рубидия в виде порошка |
| CN116631510B (zh) * | 2022-10-28 | 2024-01-12 | 中国人民解放军军事科学院军事医学研究院 | 一种用于鉴别诊断克罗恩病和溃疡性结肠炎的装置 |
| WO2024196897A1 (en) * | 2023-03-22 | 2024-09-26 | Courtland Imel | Novel methods for increasing healing speed of human and animal wounds |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4600711A (en) * | 1982-08-18 | 1986-07-15 | The University Of Kentucky Research Foundation | Composition for topical and infusion treatment of wounds and burns |
| DE3416777C2 (de) * | 1984-05-07 | 1986-11-20 | Gödecke AG, 1000 Berlin | Pharmazeutische topische Zubereitungen |
| ATE191850T1 (de) * | 1992-11-06 | 2000-05-15 | Greystone Medical Group Inc | Eichenrindenextraktverwandte synthetische zubereitungen und verfahren zur verwendung |
| AUPN104895A0 (en) * | 1995-02-10 | 1995-03-09 | Lai, John | Methods of and preparations for the treatment of ailments and disorders |
| GB9905663D0 (en) * | 1999-03-12 | 1999-05-05 | Bristol Myers Squibb Co | Iodine preparation composition |
| US20020141964A1 (en) * | 2001-01-19 | 2002-10-03 | Patterson James A. | Composition for arresting the flow of blood and method |
| IL152453A (en) * | 2000-04-28 | 2008-03-20 | Biolife Llc | Hemostatic agent including an oxyacid salt |
| US6600057B2 (en) * | 2000-12-29 | 2003-07-29 | Kimberly-Clark Worldwide, Inc. | Matrix metalloproteinase inhibitors |
-
2002
- 2002-11-27 WO PCT/US2002/038175 patent/WO2003045366A1/en not_active Ceased
- 2002-11-27 JP JP2003546869A patent/JP2005515191A/ja active Pending
- 2002-11-27 US US10/305,713 patent/US20030133991A1/en not_active Abandoned
- 2002-11-27 AU AU2002359529A patent/AU2002359529B2/en not_active Ceased
- 2002-11-27 MX MXPA04005219A patent/MXPA04005219A/es unknown
- 2002-11-27 EP EP02794072A patent/EP1461024A4/en not_active Withdrawn
- 2002-11-27 NZ NZ533252A patent/NZ533252A/xx not_active IP Right Cessation
- 2002-11-27 CA CA002468390A patent/CA2468390A1/en not_active Abandoned
-
2005
- 2005-03-15 US US11/081,119 patent/US20060029682A1/en not_active Abandoned
-
2006
- 2006-09-20 US US11/523,869 patent/US20070009611A1/en not_active Abandoned
-
2007
- 2007-07-17 US US11/779,026 patent/US20070298121A1/en not_active Abandoned
-
2009
- 2009-09-23 US US12/565,244 patent/US20100196507A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005515191A (ja) | 2005-05-26 |
| MXPA04005219A (es) | 2005-06-20 |
| EP1461024A4 (en) | 2009-03-25 |
| US20070298121A1 (en) | 2007-12-27 |
| US20100196507A1 (en) | 2010-08-05 |
| EP1461024A1 (en) | 2004-09-29 |
| AU2002359529A1 (en) | 2003-06-10 |
| US20070009611A1 (en) | 2007-01-11 |
| WO2003045366A1 (en) | 2003-06-05 |
| AU2002359529B2 (en) | 2008-02-21 |
| US20030133991A1 (en) | 2003-07-17 |
| US20060029682A1 (en) | 2006-02-09 |
| NZ533252A (en) | 2006-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002359529B2 (en) | Treatment of wounds and compositions employed | |
| EP3308793B1 (en) | Therapeutic agent for skin wound or rough skin | |
| Degreef | How to heal a wound fast | |
| Sarabahi | Recent advances in topical wound care | |
| US20070190178A1 (en) | Composition and method for the therapeutic modulation of matrix metalloproteinase | |
| US6187743B1 (en) | Composition and method for enhancing wound healing | |
| Tan et al. | The benefits of occlusive dressings in wound healing | |
| US20130251665A1 (en) | Treatment of chronic ulcerous skin lesions | |
| IE65359B1 (en) | Two-step procedure for indolent wound healing and aqueous medium and topical ointment used in connection therewith | |
| EP1372745A2 (en) | Medical dressing comprising an antimicrobial silver compound | |
| CN102105177B (zh) | 治疗皮肤损伤的药物组合物、敷料和方法,用于制备所述敷料的中间组合物和方法,以及与胶原基质缔合的铈盐的用途 | |
| US20110045072A1 (en) | Pharmaceutical composition, dressing and method for treating skin lesion, intermediate composition and process for preparing said dressing, and use of cerium salt associated with a collagen matrix | |
| EP1968627A2 (en) | Compositions for disrupting and inhibiting reconstitution of wound biofilm | |
| US20100143478A1 (en) | Treatment of inflammation and the complement and kinin cascades in a patient, particularly in chronic ulcerous skin lesions | |
| US20100183722A1 (en) | Modulation of proteases. particularly in the treatment of chronic ulcerous skin lesions | |
| Wetter et al. | Effects of zinc oxide in an occlusive, adhesive dressing on granulation tissue formation | |
| SEID et al. | A review on equine wound management and healing process | |
| US20090148394A1 (en) | Treatment of chronic ulcerous skin lesions | |
| Ray | Management of surgical wounds, wounds healing and burst abdomen | |
| El Goweini et al. | Effect of 4uercetin on Excessive Dermal Scarring | |
| KR102376345B1 (ko) | 상처 치료용 괴사조직제거 조성물 | |
| Saraswathy et al. | Patterned wound healing effect of topical recombinant human epidermal growth factor in trophic ulcers secondary to leprosy | |
| HK1150785B (en) | Pharmaceutical composition, dressing and method for treating skin lesion, intermediate composition and process for preparing said dressing, and use of cerium salt associated with a collagen matrix |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |